2022
DOI: 10.31557/apjcp.2022.23.1.125
|View full text |Cite
|
Sign up to set email alerts
|

Rapid Detection of N-RAS Gene Common Mutations in Acute Myeloid Leukemia (AML) Using High Resolution Melting (HRM) Method

Abstract: Objective: Acute myeloid leukemia is caused by the clonal proliferation of undifferentiated myeloid hematopoietic precursors. AML prognosis is highly involved in the treatment response and is determined by mutations in several genes such as N-RAS. This study aims to identify the distribution of common N-RAS mutations (codons 12, 13, and 61) in AML patients using the HRM method and confirm this method's efficiency for mutation detection by comparing its results with the sequencing data as the Gold standard meth… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 35 publications
(27 reference statements)
0
1
0
Order By: Relevance
“…Conventional chemotherapeutic agents such as cisplatin, paclitaxel, and methotrexate are cytotoxic and can directly destroy malignant cells by damaging DNA 4,5 , blocking intracellular protein synthesis 6,7 , and affecting nucleic acid metabolism thereof [8][9][10] , which are limited by the collateral damage to normal cells. Mutations in various pro-oncogenes (such as RAS, MYC, and SIS family genes) in lung cancer cells are among the important endogenous factors leading to its development [11][12][13] . Therefore, the exploration of novel anti-cancer agents with molecular targeting functions, which can also selectively inhibit lung cancer cells (low toxicity and high efficiency), is a significant entry point for the treatment of lung cancer at present.…”
mentioning
confidence: 99%
“…Conventional chemotherapeutic agents such as cisplatin, paclitaxel, and methotrexate are cytotoxic and can directly destroy malignant cells by damaging DNA 4,5 , blocking intracellular protein synthesis 6,7 , and affecting nucleic acid metabolism thereof [8][9][10] , which are limited by the collateral damage to normal cells. Mutations in various pro-oncogenes (such as RAS, MYC, and SIS family genes) in lung cancer cells are among the important endogenous factors leading to its development [11][12][13] . Therefore, the exploration of novel anti-cancer agents with molecular targeting functions, which can also selectively inhibit lung cancer cells (low toxicity and high efficiency), is a significant entry point for the treatment of lung cancer at present.…”
mentioning
confidence: 99%